Aviceda Announces Additional World-Class Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and chronic, non-resolving inflammation, is announcing the addition of world-renowned top-tier ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are: Robert Avery, MD Rishi Singh, MD Baruch Kupperm